Want to join the conversation?
$CELG President Jacqualyn Fouse said that the company expects 2016 Revlimid sales to grow to $6.6-6.7Bil, up 15% at the mid point of the range driven by volume. Pomalyst/Imnovid and Abraxane are both expected to officially reach blockbuster drug status in 2016 by each surpassing the $1Bil revenue mark.
$BABA seems to be on a roll! But increasing its yearly sales outlook from 48% to 54% seems over-expectation from the company's part, doesn't it?
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?
$YHOO is reporting today after market close. Nobody cares about this stock.